SOX Versus XELOX as Adjuvant Chemotherapy for Stage III Colorectal Cancer Patients

Inclusion Criteria:

* Signed written consent form;
* age ≥18 years old;
* randomization within 2-8 weeks after surgery;
* Performance status of the US Eastern Cancer Cooperative Group (ECOG) score 0-1;
* pathologically diagnosed as stage III colon or rectal adenocarcinoma patient;
* Accept effective contraceptive measures;
* postmenopausal women; pregnancy test negative 72 hours before randomization;
* R0 resection.

Exclusion Criteria:

* primary tumor metastasis (including tumor cells in the ascites or the occurrence of peritoneal metastasis);
* presence of clinical relevant cardiovascular disease;
* presence of disease history of central nervous system, or evidence confirmed subjects suffering from central nervous system diseases;
* presence of grade 3 (or over grade 3) peripheral neuropathy, according to the common adverse event evaluation criteria (CTCAE) v. 3.0;
* post-operative radiotherapy must be implemented in patients according to researchers' assessment,;
* presence of any unresolved toxicity left from previous anti-cancer treatment left \> grade 2 according to CTCAE, except hair loss;
* simultaneous use of targeted therapeutic drugs, such as anti-vascular endothelial growth factor (VEGF) monoclonal antibody, or anti-epidermal growth factor receptor (EGFR) monoclonal antibody;
* brain metastases or meningeal metastases;
* Insufficiency of bone marrow reserve capacity, the presence of neutrophils absolute count ≤ 1.5 × 109 / L or platelet count ≤ 75 × 109 / L, or the need for regular blood transfusion in order to maintain hemoglobin ≥ 9g / dL;
* Serum bilirubin ≥1.5 × upper limit of reference range (ULRR);
* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥2.5 × ULRR;
* serum creatinine ≥ 1.5 × ULRR or Cockcroft-Gault formula calculated creatinine clearance ≤ 50ml / min;
* Evidence of any severe or uncontrolled systemic disease (eg, unstable or decompensated breathing, heart, liver or kidney disease, HIV infection, hypertension, severe arrhythmia, diabetes, massive active bleeding);
* undergo a major surgery within 14 days prior to entering the study, or surgical incision that has not yet healed completely;
* women who are pregnant or breastfeeding, or women who are positive for pregnancy before the trial;
* subjects known to be allergic to oxaliplatin, capecitabine, S-1 or any ingredient of these products;
* combination of other anti-cancer treatment (including gonadotropin-releasing hormone agonists, anti-cancer Chinese medicine, immunotherapy), except for steroid hormones;
* In the past 5 years there are other malignant tumor history, except curative treatment of skin basal cell carcinoma and / or cervical cancer in situ;
* have a significant history of gastrointestinal damage, the researchers judge may significantly affect the absorption of S-1, including dysphagia;
* subjects known suffering dihydropyrimidine dehydrogenase (DPD) deficiency.